Table 2.
Baseline characteristics of patients included in predictive modeling analysis.
| No Anaphylaxis (N = 60) | Anaphylaxis (N = 4) | P value | |
|---|---|---|---|
| Age in years, median (range) | 55.5 (30–80) | 73.5 (57–76) | 0.012 |
| Gender, N (%) | >0.999 | ||
| Male | 38 (63.3) | 3 (75) | |
| Female | 22 (36.7) | 1 (25) | |
| Allergy History, N (%) | |||
| Asthma | 1 (1.7) | 0 (0) | >0.999 |
| Food allergy | 0 (0) | 0 (0) | |
| Drug allergy (any) | 1 (1.7) | 0 (0) | >0.999 |
| Laboratory findings in median (range) | |||
| Eosinophil (numbers/μL) | 145 (0–900) | 205 (90–2,088) | 0.227 |
| AST (IU/L) | 20.5 (7–166) | 22 (21–32) | 0.428 |
| ALT (IU/L) | 20 (6–138) | 16.5 (6–22) | 0.285 |
| BUN (mg/dL) | 12.5 (4.5–31.0) | 14.8 (13.6–22.1) | 0.367 |
| Creatinine (mg/dL) | 0.8 (0.3–1.4) | 0.9 (0.7–0.9) | 0.718 |
| EGFR (ml/min/1.73 m2) | >90 (52->90) | 87 (61->90) | 0.353 |
| Allergy serum test (positive ratio) | |||
| Cetuximab sIgE | 0/60 (0%) | 4/4 (100%) | < 0.001 |
| Cetuximab sIgE | 0/60 (0%) | 4/4 (100%) | < 0.001 |
| Alpha-gal sIgE | 0/60 (0%) | 4/4 (100%) | < 0.001 |
| Beef sIgE | 0/60 (0%) | 4/4 (100%) | < 0.001 |
| Allergy skin test (positive ratio) | |||
| Cetuximab SPT | 0/60 (0%) | 2/2 (100%) | < 0.001 |
| Premedication, N (%) | |||
| Anti-histamine | 60 (100) | 4 (100) | |
| Corticosteroid | 60 (100) | 4 (100) | |
| Combination therapy, N (%) | 0.502 | ||
| Irinotecan | 2 (3.3) | 0 (0) | |
| Fluorouracil and Irinotecan | 51 (85.0) | 3 (75) | |
| Fluorouracil and Oxaliplatin | 7 (11.7) | 1 (25) |
EGFR, estimated glomerular filtration rate; sIgE, specific immunoglobulin E; O.D, optical density measured by ELISA; SPT, skin prick test; Gender, allergy history, cetuximab SPT, and combination therapy were analyzed using Fisher's exact test. Age, laboratory findings, and sIgEs were analyzed using a Mann-Whitney U test. Values with a P value less than 0.05 are displayed in bold.